BioMotiv, the for-profit accelerator of The Harrington Project, is the lead funder of SapVax. BioMotiv aims to advance a portfolio of discoveries into new medicines through an innovative, mission-driven model that efficiently aligns capital and collaborations for the benefit of inventors and investors, and ultimately physicians and patients.
Learn more about BioMotiv here.
Auckland UniServices Limited, the commercial research, knowledge transfer and custom education company of the University of Auckland, has invested in SapVax. It is the manager of the University of Auckland’s seed fund, the University of Auckland Inventors’ Fund, a $20 million fund dedicated to investing in technology and start-ups developed by the staff and students of the University.
Learn more about Uniservices here.
In addition to investment from BioMotiv, SapVax has received support from The Harrington Project through the Harrington Discovery Institute at University Hospitals in Cleveland.
Learn more about The Harrington Project and the Harrington Discovery Institute here.
Innovator Capital ("ICL"), a London based specialist investment bank advising emerging, sustainable technology, ICT and life science companies, has invested in SapVax. Established in 2003, ICL provides strategic and capital markets advice, M&A, licensing and intellectual property services.
Learn more about ICL here.